These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 8173071)
21. Breast cancer prevention. Euhus DM; Diaz J Breast J; 2015; 21(1):76-81. PubMed ID: 25413630 [TBL] [Abstract][Full Text] [Related]
22. Epidemiology of breast cancer. Marchant DJ Clin Obstet Gynecol; 1982 Jun; 25(2):387-92. PubMed ID: 7105514 [TBL] [Abstract][Full Text] [Related]
23. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. Meiser B; Butow P; Friedlander M; Schnieden V; Gattas M; Kirk J; Suthers G; Haan E; Tucker K J Clin Oncol; 2000 Jun; 18(11):2250-7. PubMed ID: 10829045 [TBL] [Abstract][Full Text] [Related]
24. Chemoprevention of breast cancer in the older patient. Minton SE Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075 [TBL] [Abstract][Full Text] [Related]
25. Management of women with a hereditary predisposition for breast cancer. Jatoi I; Benson JR Future Oncol; 2016 Oct; 12(19):2277-88. PubMed ID: 27384952 [TBL] [Abstract][Full Text] [Related]
26. Mammography screening: A major issue in medicine. Autier P; Boniol M Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783 [TBL] [Abstract][Full Text] [Related]
27. Risk assessment: controversies and management of moderate- to high-risk individuals. Brown P Breast J; 2005; 11 Suppl 1():S11-9. PubMed ID: 15725110 [TBL] [Abstract][Full Text] [Related]
28. Absolute risk of breast cancer for Australian women with a family history. Taylor R; Boyages J Aust N Z J Surg; 2000 Oct; 70(10):725-31. PubMed ID: 11021486 [TBL] [Abstract][Full Text] [Related]
30. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Levine M; Moutquin JM; Walton R; Feightner J; CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210 [TBL] [Abstract][Full Text] [Related]
32. [Prophylactic mastectomy in women at high risk for breast cancer: indications and options]. Scheufler O; Fritschen Uv Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):239-47. PubMed ID: 18716986 [TBL] [Abstract][Full Text] [Related]
33. Should women at increased risk for breast and ovarian cancer be randomized to prophylactic surgery? An ethical and empirical assessment. Tambor ES; Bernhardt BA; Geller G; Helzlsouer KJ; Doksum T; Holtzman NA J Womens Health Gend Based Med; 2000 Apr; 9(3):223-33. PubMed ID: 10787220 [TBL] [Abstract][Full Text] [Related]
34. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. Schrag D; Kuntz KM; Garber JE; Weeks JC JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701 [TBL] [Abstract][Full Text] [Related]
35. Identification and management of the woman at increased risk for breast cancer development. Morrow M Breast Cancer Res Treat; 1994; 31(1):53-60. PubMed ID: 7981457 [TBL] [Abstract][Full Text] [Related]
36. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Loehberg CR; Jud SM; Haeberle L; Heusinger K; Dilbat G; Hein A; Rauh C; Dall P; Rix N; Heinrich S; Buchholz S; Lex B; Reichler B; Adamietz B; Schulz-Wendtland R; Beckmann MW; Fasching PA Breast Cancer Res Treat; 2010 May; 121(1):101-10. PubMed ID: 20306293 [TBL] [Abstract][Full Text] [Related]
37. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508 [TBL] [Abstract][Full Text] [Related]
38. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. Hoogerbrugge N; Bult P; de Widt-Levert LM; Beex LV; Kiemeney LA; Ligtenberg MJ; Massuger LF; Boetes C; Manders P; Brunner HG J Clin Oncol; 2003 Jan; 21(1):41-5. PubMed ID: 12506168 [TBL] [Abstract][Full Text] [Related]
39. [Hormone replacement therapy in menopause and risk of breast cancer]. Clavel-Chapelon F; Hill C Presse Med; 2000 Oct; 29(31):1688-93. PubMed ID: 11094609 [TBL] [Abstract][Full Text] [Related]
40. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]